Abstract
Focal adhesion kinase (FAK) is well established as a regulator of cell migration, but whether and how the closely related proline-rich tyrosine kinase 2 (Pyk2) regulates fibroblast motility is still under debate. Using mouse embryonic fibroblasts (MEFs) from Pyk2-/- mice, we show here, for the first time, that lack of Pyk2 significantly impairs both random and directed fibroblast motility. Pyk2-/- MEFs show reduced cell-edge protrusion dynamics, which is dependent on both the kinase and protein-protein binding activities of Pyk2. Using bioinformatics analysis of in vitro high- throughput screens followed by text mining, we identified CrkI/II as novel substrates and interactors of Pyk2. Knockdown of CrkI/II shows altered dynamics of cell-edge protrusions, which is similar to the phenotype observed in Pyk2-/- MEFs. Moreover, epistasis experiments suggest that Pyk2 regulates the dynamics of cell-edge protrusions via direct and indirect interactions with Crk that enable both activation and down-regulation of Crk-mediated cytoskeletal signaling. This complex mechanism may enable fine-tuning of cell-edge protrusion dynamics and consequent cell migration on the one hand together with tight regulation of cell motility, a process that should be strictly limited to specific time and context in normal cells, on the other hand.
Original language | English |
---|---|
Article number | 0640 |
Journal | Molecular Biology of the Cell |
Volume | 32 |
Issue number | 21 |
DOIs | |
State | Published - 1 Nov 2021 |
Bibliographical note
Publisher Copyright:© 2021 Lukic et al.
Funding
This work was supported by grants from the Israel Science Foundation (grants number 1462/17 and 2142/21), the Israel Cancer Research Fund (grant number 20-101-PG), and the Israel Cancer Association (grant number 20210071) (to H.G.-H.) and a grant from the Israel Science Foundation (grant number 3308/20) (to R.Z.-B.). We thank Anthony Koleske for his kind assistance and advice in the in vitro kinase and binding assays and Bruce Mayer for his kind gift of Crk constructs.
Funders | Funder number |
---|---|
Israel Cancer Research Fund | 20-101-PG |
Israel Cancer Association | 20210071, 3308/20 |
Israel Science Foundation | 2142/21, 1462/17 |